Navigation Links
Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
Date:2/1/2012

lts may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2010 and in Auxilium's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.

'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
2. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
4. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. Announces Publication of U.S. CPT® Codes and Related Reimbursement Rates for XIAFLEX®
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
8. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
9. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
10. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
11. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:7/27/2015)... ... 2015 , ... The FSH Society , the Massachusetts-based ... muscular dystrophy (FSHD), today announced the introduction of the first-ever care guideline for ... published today. , This new guideline condenses the results of nearly 60 ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Looking ... healthy smile? Horizon Blue Cross Blue Shield of New Jersey has enhanced its Dental ... to take care of their teeth. , “Horizon is committed to offering our ...
(Date:7/27/2015)... AZ (PRWEB) , ... July 27, 2015 , ... The ... who are aging out of the foster care system to get into and complete ... Charitable Trust, was introduced at an event today with partners from across the ...
(Date:7/27/2015)... ... July 27, 2015 , ... A Harris County jury awarded a group ... Canadian stock promoter Robert Kubbernus based on findings of fraud and violations of the ... by the court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program ... to support its mission of reducing the number of deaths and injuries occurring from ... and their families. PursuitSAFETY works with the police to find better and safer ...
Breaking Medicine News(10 mins):Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
... model that looks at different strategies for curbing ... isolation may be effective approaches when patients are ... superbugs, such as methicillin-resistant Staphylococcus aureas (MRSA), and ... infections, this type of modeling, if used to ...
... problem that needs to be addressed next is the epidemic ... together to discuss the latest in pain research and treatment ... Pain Medicine (AAPM), February 12-16 at the Gaylord Palms in ... help of their physicians, have been asked to stop smoking ...
... otherwise healthy people have similar survival rates to younger ... older patients can undergo lung transplantation and have good ... patients from having the procedure, a new study says. ... Medical Center reviewed the records of 48 UCLA patients ...
... Proposed Changes in ... Lifesaving Effort, WASHINGTON, Feb. 16 As President Bush ... funded by the,President,s Emergency Plan for AIDS Relief (PEPFAR), the ... request, AIDS Healthcare,Foundation (AHF) ( http://www.aidshealth.org ) today cautioned the ...
... release is also available in French . ... flushing toxic chemicals into the ecosystem through municipal sewer ... comes from an unlikely source: estrogen. , After an ... amounts of estrogen present in municipal wastewater discharges can ...
... Crowder &,DeGaris, P.C. (http://www.cwcd.com ), has filed ... the United States, who allegedly suffered,permanent kidney damage ... to prevent excessive bleeding during coronary,artery bypass graft ... to CBS News, 60 Minutes will report Sunday ...
Cached Medicine News:Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:Bush AIDS Legacy at Risk, Says AHF 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 3Health News:60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 2
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: